DrugPatentWatch Database Preview

Hospira Company Profile

« Back to Dashboard

What is the competitive landscape for HOSPIRA, and when can generic versions of HOSPIRA drugs launch?

HOSPIRA has five hundred and twelve approved drugs.

There are seven US patents protecting HOSPIRA drugs. There are eleven tentative approvals on HOSPIRA drugs.

There are forty-two patent family members on HOSPIRA drugs in thirty-four countries and three hundred and fifty supplementary protection certificates in sixteen countries.

Summary for Hospira

International Patents:	42
US Patents:	7
Tradenames:	329
Ingredients:	206
NDAs:	512
Patent Litigation for Hospira:	See patent lawsuits for Hospira

Drugs and US Patents for Hospira

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	FUROSEMIDE	furosemide	INJECTABLE;INJECTION	075241-001	May 28, 1999	AP	RX	No	No
Hospira Inc	AMPICILLIN AND SULBACTAM	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	090646-001	Dec 21, 2011		DISCN	No	No
Hospira	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%	heparin sodium	INJECTABLE;INJECTION	018911-003	Jan 30, 1985		DISCN	No	No
Hospira	BUPIVACAINE HYDROCHLORIDE	bupivacaine hydrochloride	INJECTABLE;INJECTION	018053-003	Approved Prior to Jan 1, 1982	AP	RX	No	No
Hospira	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	sodium chloride	SOLUTION;IRRIGATION	017670-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	SOLUTION;INTRAVENOUS	070737-001	May 6, 1987	AP	RX	No	Yes

Expired US Patents for Hospira

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hospira	BRETYLOL	bretylium tosylate	INJECTABLE;INJECTION	017954-001	Approved Prior to Jan 1, 1982	RE29618
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-003	Mar 13, 2013	4,910,214*PED
Hospira Inc	NIPENT	pentostatin	INJECTABLE;INJECTION	020122-001	Oct 11, 1991	3,923,785
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-002	Mar 13, 2013	4,910,214*PED
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-003	Mar 13, 2013	6,716,867*PED
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-002	Mar 13, 2013	6,716,867*PED

Paragraph IV (Patent) Challenges for HOSPIRA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	100 mcg/mL		2009-04-08
	Injection	4 mcg/mL, 20 mL vials		2015-09-30
	Injection	1 mg/mL, 50 mL vials		2011-12-16
	Injection	4 mcg/mL, 50 mL and 100 mL vials		2013-12-26
	Injection	100 mg/mL, 2.5 mL vials		2007-09-24

International Patents for Hospira Drugs

Country	Patent Number	Estimated Expiration
Japan	5927680
Hong Kong	1249429
Portugal	2648520
China	107802624
South Africa	201301649
Chile	2013000815

Supplementary Protection Certificates for Hospira Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1732523	300925	Netherlands		PRODUCT NAME: PATIROMER SORBITEX CALCIUM EN ALLE ZOUTEN DAARVAN
1385870	C 2011 014	Romania		PRODUCT NAME: BOCEPREVIR(1R,2S,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/704/001; DATE OF NATIONAL AUTHORISATION: 20110718; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/704/001; DATE OF FIRST AUTHORISATION IN EEA: 20110718
0809498	SPC/GB10/012	United Kingdom		PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0300652	2003C/005	Belgium		PRODUCT NAME: CHLORHYDRATE DE DEXMEDETOMIDINE; REGISTRATION NO/DATE: EU/2/02/033/001 20020903
0521471	C300125	Netherlands		PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
1115417	SPC/GB06/024	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Hospira
• Hospira Inc
• Hospira Worldwide